Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Structural and functional characterization of a triple mutant form of S100A7 defective for Jab1 binding.

West NR, Farnell B, Murray JI, Hof F, Watson PH, Boulanger MJ.

Protein Sci. 2009 Dec;18(12):2615-23. doi: 10.1002/pro.274.


Structural characterization of S100A15 reveals a novel zinc coordination site among S100 proteins and altered surface chemistry with functional implications for receptor binding.

Murray JI, Tonkin ML, Whiting AL, Peng F, Farnell B, Cullen JT, Hof F, Boulanger MJ.

BMC Struct Biol. 2012 Jul 2;12:16. doi: 10.1186/1472-6807-12-16.


The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer.

Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH.

Cancer Res. 2005 Jul 1;65(13):5696-702.


Identification and characterization of binding sites on S100A7, a participant in cancer and inflammation pathways.

León R, Murray JI, Cragg G, Farnell B, West NR, Pace TC, Watson PH, Bohne C, Boulanger MJ, Hof F.

Biochemistry. 2009 Nov 10;48(44):10591-600. doi: 10.1021/bi901330g.


S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.

Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH.

Breast Cancer Res. 2004;6(4):R308-15. Epub 2004 Apr 26.


Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function.

Wolf R, Ruzicka T, Yuspa SH.

Amino Acids. 2011 Oct;41(4):789-96. doi: 10.1007/s00726-010-0666-4. Epub 2010 Jul 2. Review.


Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer.

Wang J, Barnes RO, West NR, Olson M, Chu JE, Watson PH.

Breast Cancer Res. 2008;10(3):R51. doi: 10.1186/bcr2105. Epub 2008 Jun 6.


Psoriasin interacts with Jab1 and influences breast cancer progression.

Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC, Watson PH.

Cancer Res. 2003 Apr 15;63(8):1954-61.


Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.

Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner AM, Le XF, Liao WS, Claret FX.

Breast Cancer Res. 2011 Jun 20;13(3):R65. doi: 10.1186/bcr2902.


Characterization of a unique motif in LIM mineralization protein-1 that interacts with jun activation-domain-binding protein 1.

Sangadala S, Yoshioka K, Enyo Y, Liu Y, Titus L, Boden SD.

Mol Cell Biochem. 2014 Jan;385(1-2):145-57.


Direct binding of Copine3 with Jab1 activates downstream ErbB2 signaling and motility in SKBr3 breast cancer cells.

Choi HY, Park N, Na JB, Ko ES, Park JY, Yoo JC.

Oncol Rep. 2016 Feb;35(2):1147-52. doi: 10.3892/or.2015.4472. Epub 2015 Dec 2.


Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.

Wang H, Liu XB, Chen JH, Wang QQ, Chen JP, Xu JF, Sheng CY, Ni QC.

Exp Mol Pathol. 2014 Oct;97(2):191-201. doi: 10.1016/j.yexmp.2014.07.012. Epub 2014 Jul 16.


Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis.

Webb M, Emberley ED, Lizardo M, Alowami S, Qing G, Alfia'ar A, Snell-Curtis LJ, Niu Y, Civetta A, Myal Y, Shiu R, Murphy LC, Watson PH.

BMC Cancer. 2005 Feb 17;5:17.


Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.

Deol YS, Nasser MW, Yu L, Zou X, Ganju RK.

J Biol Chem. 2011 Dec 30;286(52):44845-54. doi: 10.1074/jbc.M111.225466. Epub 2011 Oct 20.


S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer.

West NR, Watson PH.

Oncogene. 2010 Apr 8;29(14):2083-92. doi: 10.1038/onc.2009.488. Epub 2010 Jan 18.


Differential role of psoriasin (S100A7) in estrogen receptor α positive and negative breast cancer cells occur through actin remodeling.

Sneh A, Deol YS, Ganju A, Shilo K, Rosol TJ, Nasser MW, Ganju RK.

Breast Cancer Res Treat. 2013 Apr;138(3):727-39. doi: 10.1007/s10549-013-2491-4. Epub 2013 Mar 28.


The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1.

Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B, Jazag A, Ohta M, Imamura J, Ikenoue T, Ijichi H, Kawabe T, Isobe T, Omata M.

Oncogene. 2006 Jan 26;25(4):633-42.


Differential occurrence of S100A7 in breast cancer tissues: a proteomic-based investigation.

Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, Riili I, Lupo C, Roz E, Pucci-Minafra I.

Proteomics Clin Appl. 2012 Aug;6(7-8):364-73. doi: 10.1002/prca.201100072.


Supplemental Content

Support Center